Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

It's Thursday morning, 11:50 a.m. ET -- and Eli Lilly (NYSE: LLY) stock is off to the races! This morning, the ...

the pharmaceutical sector has captivated investors thanks in large part to novel medications used to treat chronic weight management and diabetes. While Lilly's success with GLP-1 drugs is ...

Novo Nordisk's proprietary active drug is semaglutide, used in its flagship GLP-1 agonists -- Ozempic for type 2 diabetes and Wegovy ... prefer a pill to a needle.

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.24. Operator: Welcome to the Rani ...

In the small intestine, a self-inflating balloon creates the pressure needed to inject the dissolvable micro needle and ... version of the GLP-1 and GLP-2 ProGen's drug was that PG-102 had much ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...